Welcome to our dedicated page for Galmed Pharmaceu news (Ticker: GLMD), a resource for investors and traders seeking the latest updates and insights on Galmed Pharmaceu stock.
Galmed Pharmaceuticals Ltd. develops Aramchol, an SCD1 inhibitor drug candidate, as a clinical-stage biopharmaceutical company focused on liver disease, cardiometabolic disease and gastrointestinal oncology therapeutics. Company updates frequently cover Aramchol development in NASH/MASH and fibrosis, combination approaches, patent activity, scientific presentations and efforts to expand the pipeline into oncology and cardiometabolic indications.
Recent developments also include collaborations and formulation work tied to Aramchol-based research, including human organoid models for cardiac fibrosis, preclinical evaluation in metastatic brain cancers and brain-penetrating delivery approaches for CNS-related applications. Other recurring corporate news includes annual-report filings, shareholder communications and Nasdaq listing compliance matters.
Galmed Pharmaceuticals (NASDAQ: GLMD) announced that its wholly owned subsidiary Colospan completed a first-in-human, prospective single-arm feasibility study of a novel intraoperative colon tissue quality assessment platform in 32 colorectal cancer patients undergoing elective surgery at three leading medical centers in Israel.
The study demonstrated that quantitative measurement of colon tissue compliance using a novel ex-vivo methodology was technically feasible, with successful measurements in all 32 patients and no measurement failures or procedure-related technical issues. These results establish a clinical foundation for continued development of an intraoperative device to provide surgeons with objective, real-time tissue quality data, complementing Colospan’s CG-100 intraluminal bypass device and supporting Galmed’s strategy to build a diversified GI oncology and colorectal surgery portfolio.
Galmed (NASDAQ: GLMD) reported new pre-clinical data showing that combining its SCD1 inhibitor Aramchol with enzalutamide (Xtandi) produced a 3–4-fold increase in cell death versus enzalutamide alone in the VCaP prostate cancer cell line, with the interaction strengthening over time.
The VCaP line expresses wild-type androgen receptor, AR-V7 and TMPRSS2-ERG, and originates from metastatic mCSPC. Galmed previously observed synergistic, greater-than-additive killing when Aramchol was combined with docetaxel across several tumor types, including prostate cancer cells.
According to Galmed, Xtandi global sales reached about $8 billion in 2024 and $6 billion in 2025, roughly 4% of Pfizer’s revenue. Main enzalutamide patents expire in 2026 in Europe and 2027 in the US, with a US price cut scheduled for 2027. Galmed has submitted a patent application covering the Aramchol–enzalutamide combination and plans to begin partnership discussions based on these findings.
Galmed Pharmaceuticals (NASDAQ: GLMD) reported progress in developing an orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol as a potential disease-modifying therapy for Parkinson's disease. According to Galmed, Aramchol meglumine is currently the only SCD1 inhibitor with an established clinical safety profile and confirmed blood‑brain barrier penetration.
The new ODF showed approximately 150% higher systemic bioavailability and about 300% higher CNS exposure versus conventional oral administration, with rapid buccal/sublingual absorption and reduced first‑pass metabolism. Galmed highlights that the water‑free, fast‑dissolving film may address dysphagia affecting up to 80% of Parkinson's patients and sees Aramchol's CNS‑optimized delivery and mechanism-based approach as a differentiated, out‑licensing‑ready program in a $6+ billion global Parkinson's therapeutics market.
Galmed (NASDAQ: GLMD) announced the development, in collaboration with Barcode Nanotech, of a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor Aramchol that redirects biodistribution from liver hepatocytes to heart muscle, enabling targeted penetration of heart tissue using FDA-approved lipids.
The platform combines advanced formulation science, in vivo screening of hundreds of nanoparticle candidates, and AI-enabled analysis to optimize cardiac delivery, including to fibroblasts and other disease-driving cardiac cells. According to Galmed, this work supports longer-term Aramchol-based cardiac programs alongside its current GI and oncology focus, aiming to create disease-modifying cardiac fibrosis therapies.
Galmed Pharmaceuticals (NASDAQ: GLMD) completed its acquisition of Colospan, gaining CG-100, a CE-marked colorectal device commercial-ready in the EU/Israel with a dedicated German OPS code.
Restructured terms replace a $2.0M share issue with an $800K extra cash payment and an up-to-$2.0M tiered earnout starting Q3 2027. CG-100 has supportive clinical data from four trials (97 patients) and may generate revenue in 2026.
Galmed Pharmaceuticals (NASDAQ: GLMD) signed a definitive agreement to acquire Colospan, creating a GI-focused medtech and biopharmaceutical platform targeting a $6 billion colorectal surgery market.
Colospan’s CG-100 intraluminal bypass device holds FDA Breakthrough Device status, is CE marked, in a U.S. pivotal IDE trial, and planned for EU launch in H2 2026. Deal consideration totals $4.5 million plus a planned $6 million EU launch investment, with closing expected in Q2 2026.
Galmed (NASDAQ: GLMD) and Tissue Dynamics reported preclinical data on a combination of Aramchol Meglumine and a selective PPARα agonist in human cardiac organoids.
The combo identified a previously unknown metabolic pathway in cardiac fibrosis and reduced fibrotic burden about fourfold (p<0.001), while preserving cardiac muscle and metabolic function. A new patent was filed and IND-enabling preparations are underway.
Galmed (NASDAQ: GLMD) reported Phase 1 pharmacokinetics results for its oral formulation Aramchol meglumine (AM) in healthy subjects (Study AM-001).
Single 400mg and 200mg AM doses showed approximately 5-fold and 3-fold higher Aramchol bioavailability versus 300mg Aramchol free acid (AA) tablets. The 400mg AM once-daily dose is intended to match exposure from AA 300mg twice daily.
According to Galmed, this transition may enable GMP clinical batch production, extend Aramchol IP protection, potentially cut drug cost of goods by ~50%, and improve patient convenience and compliance in future MASH and GI oncology uses.
Galmed (NASDAQ: GLMD) and Tissue Dynamics announced a collaboration to build a human-centered chronic cardiac fibrosis platform to accelerate Aramchol-based therapeutics. The platform uses vascularized, multichambered cardiac organoids with embedded metabolic sensors, AI, and automation to test >20,000 organoids in parallel.
The model targets post-MI remodeling and HFpEF, links SCD1-driven lipid metabolism to fibrosis and impaired repair, and aims to support preclinical evaluation of dosing, combinations, and disease-stage interventions.
Galmed (NASDAQ: GLMD) announced on April 14, 2026 a research collaboration with Tel Aviv University (via Ramot) to evaluate its brain-penetrant SCD1 inhibitor Aramchol as a targeted therapy for p53-deficient metastatic brain cancers. The collaboration will use TAU's 3D in vitro and in vivo models to validate Aramchol's efficacy and support ongoing clinical work at Virginia Commonwealth University's Massey Cancer Center.